Notable clinical activity of immune checkpoint inhibitors with or without brentuximab vedotin in relapsed or refractory gray zone lymphoma

Key Points

• The aim is to evaluate the clinical efficacy of immune checkpoint inhibitors alone or in combination with brentuximab vedotin in gray zone lymphoma.
• Participants with relapsed or refractory gray zone lymphoma were treated with immune checkpoint inhibitors with or without brentuximab vedotin.
• Clinical activity was measured using standard criteria for response evaluation.
• Significant clinical responses were observed among patients receiving combined treatment.
• Improved progression-free survival rates were noted compared to historical data without intervention.